Lista de obras - Ulrik Lassen - Dominio Público Uruguay

18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)

scientific article published on 01 July 1999

18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma

artículo científico publicado en 2015

A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

artículo científico publicado en 2010

A comparison of endoscopic ultrasound guided biopsy and positron emission tomography with integrated computed tomography in lung cancer staging

artículo científico publicado en 2009

A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers

scientific article published on 11 November 2014

A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

artículo científico publicado en 2012

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

artículo científico publicado en 2010

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

artículo científico publicado en 2015

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours ⬇️

artículo científico publicado el 24 de enero de 2012

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

artículo científico publicado en 2012

A prospective PET study of patients with glioblastoma multiforme

artículo científico publicado en 2006

A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis

artículo científico publicado en 2006

ANGI-11VEGF-C CONTRIBUTES TO AUTOCRINE VEGFR2 SIGNALING AND AFFECTS CELL VIABILITY AND TUMOR GROWTH IN GLIOBLASTOMA.

artículo científico publicado en 2015

Actively personalized vaccination trial for newly diagnosed glioblastoma

scientific article published on 19 December 2018

Amantadine in influenza

artículo científico publicado en 1992

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

artículo científico publicado en 2016

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

artículo científico publicado en 2009

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.

artículo científico publicado en 2011

Brain metastases in small-cell lung cancer

artículo científico publicado en 1995

Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

artículo científico publicado en 2010

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

artículo científico publicado en 2010

Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factors

artículo científico publicado en 2017

Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma

artículo científico publicado en 2015

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

artículo científico publicado en 2017

Current therapy of small cell lung cancer

artículo científico publicado en 1998

Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.

artículo científico publicado en 2015

Detection of copy number alterations in cell-free tumor DNA from plasma

artículo científico publicado en 2017

Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

artículo científico publicado en 2016

Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

artículo científico

EPID-28PROGNOSTIC AND PREDICTIVE BIOMARKERS IN RECURRENT WHO GRADE 3 GLIOMA PATIENTS TREATED WITH BEVACIZUMAB AND IRINOTECAN.

artículo científico publicado en 2015

Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series

artículo científico publicado en 2015

Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trial

scientific article published on 01 September 2005

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

artículo científico publicado en 2015

FDG-PET imaging in small cell lung cancer: any value?

artículo científico publicado en 2002

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

artículo científico publicado en 2016

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

artículo científico publicado en 2015

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

artículo científico

How I treat NTRK gene fusion-positive cancers

artículo científico publicado en 2019

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

artículo científico publicado en 2018

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

artículo científico publicado en 2011

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

scientific article published on 04 November 2020

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

artículo científico publicado en 1995

MTR-18PREDICTIVE BIOMARKERS OF BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS.

artículo científico publicado en 2015

Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer

artículo científico publicado en 2010

Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission tomography

artículo científico publicado en 1998

Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial.

artículo científico publicado en 2010

Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction

artículo científico publicado en 2005

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

artículo científico publicado en 2014

Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress?

artículo científico publicado en 1998

P16.23A COMPARISON OF 18F-FET AND 18F-FLT MICROPET FOR THE ASSESSMENT OF ANTI-VEGF EFFICACY IN AN ORTHOTOPIC MURINE MODEL OF GLIOBLASTOMA.

artículo científico publicado en 2014

P17.91CLINICAL VARIABLES SERVE AS PREDICTIVE FACTORS IN A MODEL FOR CLINICAL RESPONSE TO BEVACIZUMAB IN RECURRENT GLIOBLASTOMA MULTIFORME: AN OBSERVATIONAL STUDY OF A COHORT OF CONSECUTIVE NON-SELECTED PATIENTS FROM A SINGLE INSTITUTION.

artículo científico publicado en 2014

PET-CT in preoperative staging of lung cancer

artículo científico publicado en 2011

PET/CT imaging in response evaluation of patients with small cell lung cancer

artículo científico publicado en 2006

Personalized oncology: genomic screening in phase 1.

artículo científico publicado en 2014

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.

artículo científico

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

artículo científico publicado en 2015

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

artículo científico publicado en 2016

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.

artículo científico publicado en 2012

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

artículo científico publicado en 2020

Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.

artículo científico publicado en 2012

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme

artículo científico publicado en 2012

Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease

artículo científico publicado en 2008

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme

artículo científico publicado el 1 de abril de 2013

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

scientific article published on 21 October 2011

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

artículo científico publicado en 2013

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

artículo científico publicado en 2017

Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial.

artículo científico publicado en 2011

Preoperative staging of lung cancer with combined PET-CT.

artículo científico publicado en 2009

Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients

artículo científico publicado en 2014

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

artículo científico publicado en 2010

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

scientific article published on 01 February 2019

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.

artículo científico publicado en 2013

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up

scientific article published on 01 April 1996

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

artículo científico publicado en 2015

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.

artículo científico publicado en 2014

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

artículo científico publicado en 2014

The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysis.

artículo científico publicado en 2013

The role of nuclear medicine in the diagnosis of cancer of unknown origin.

artículo científico publicado en 2004

The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts

artículo científico publicado en 2014

Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial

artículo científico publicado en 2007

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

artículo científico publicado en 2017

Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma

artículo científico publicado en 2015

Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours

artículo científico publicado en 2003

[Small cell lung cancer]

artículo científico publicado en 1996

[The genome and cancer treatment] ⬇️

artículo científico publicado en 2014

Lista de obras de Ulrik Lassen

18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)

18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma

A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas

A comparison of endoscopic ultrasound guided biopsy and positron emission tomography with integrated computed tomography in lung cancer staging

A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers

A phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours ⬇️

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

A prospective PET study of patients with glioblastoma multiforme

A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis

ANGI-11VEGF-C CONTRIBUTES TO AUTOCRINE VEGFR2 SIGNALING AND AFFECTS CELL VIABILITY AND TUMOR GROWTH IN GLIOBLASTOMA.

Actively personalized vaccination trial for newly diagnosed glioblastoma

Amantadine in influenza

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab.

Brain metastases in small-cell lung cancer

Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factors

Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

Current therapy of small cell lung cancer

Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer.

Detection of copy number alterations in cell-free tumor DNA from plasma

Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan

Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities

EPID-28PROGNOSTIC AND PREDICTIVE BIOMARKERS IN RECURRENT WHO GRADE 3 GLIOMA PATIENTS TREATED WITH BEVACIZUMAB AND IRINOTECAN.

Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series

Endoscopic ultrasound guided biopsy performed routinely in lung cancer staging spares futile thoracotomies: preliminary results from a randomised clinical trial

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

FDG-PET imaging in small cell lung cancer: any value?

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors.

How I treat NTRK gene fusion-positive cancers

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

MTR-18PREDICTIVE BIOMARKERS OF BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS.

Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer

Metabolic and hemodynamic evaluation of brain metastases from small cell lung cancer with positron emission tomography

Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial.

Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.

Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress?

P16.23A COMPARISON OF 18F-FET AND 18F-FLT MICROPET FOR THE ASSESSMENT OF ANTI-VEGF EFFICACY IN AN ORTHOTOPIC MURINE MODEL OF GLIOBLASTOMA.

P17.91CLINICAL VARIABLES SERVE AS PREDICTIVE FACTORS IN A MODEL FOR CLINICAL RESPONSE TO BEVACIZUMAB IN RECURRENT GLIOBLASTOMA MULTIFORME: AN OBSERVATIONAL STUDY OF A COHORT OF CONSECUTIVE NON-SELECTED PATIENTS FROM A SINGLE INSTITUTION.

PET-CT in preoperative staging of lung cancer

PET/CT imaging in response evaluation of patients with small cell lung cancer

Personalized oncology: genomic screening in phase 1.

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.

Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme

Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme

Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial.

Preoperative staging of lung cancer with combined PET-CT.

Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients

Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma

Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

The optimality of different strategies for supplemental staging of non-small-cell lung cancer: a health economic decision analysis.

The role of nuclear medicine in the diagnosis of cancer of unknown origin.

The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts